The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
A Crisis in the Treatment of Osteoporosis
Abstract
The field of osteoporosis may be coming full circle, and that is not good for the millions of older women and men who will suffer painful and disabling spine and hip fractures—fractures that might have been prevented. As physicians, we are now watching as the fundamental progress made to reduce fractures and dramatically improve the quality of life of our patients during the past 30 years unravels. Osteoporosis was long considered an inevitable consequence of aging, in which the typical scenario played out with remarkable consistency: "Grandma" developed the characteristic "dowager's hump," later fractured her hip, was forced to leave her home and languish in pain and immobility in a nursing home, where she finally succumbed to the complications of that existence with a premature and avoidable death. However, over the course of the lifetimes of at least some of us, the scientific and medical community made remarkable advances in the diagnosis and treatment of osteoporosis. Epidemiological studies clearly defined the patterns and risk factors for age-related bone loss. Systematic studies conducted in animals and in humans defined the mechanisms of bone loss due to estrogen deficiency, aging, glucocorticoids, and many other factors. These fundamental advances in the understanding of the pathogenesis of osteoporosis drove the development of new treatments including estrogen, SERMs, teriparatide, and denosumab, with abaloparatide, romosozumab, and odanacatib on the horizon. The field also benefited by the fortuitous discovery that bisphosphonates, which were originally developed for other purposes,1 also turned out to disable osteoclasts and were developed into the most widely-used drugs today to prevent and treat osteoporosis. In 2016, we should be celebrating these triumphs of science and medicine because, by these criteria, we have made remarkable progress toward our goal of markedly decreasing the burden of a devastating disease. We should be viewing the future for our patients with osteoporosis with unparalleled optimism, because we now have several drugs that can substantially reduce fracture incidence, by as much as 70% in the case of vertebral fractures.2 Thus, although physicians still struggle to treat many other conditions that are currently intractable, including Alzheimer's disease and many cancers, the good news is that the prevention of fractures is clearly within our reach. And yet, despite the development of several effective drugs to prevent fractures, many patients, even those who unequivocally need treatment, are either not being prescribed osteoporosis medications at all, or when prescribed, refuse to take them. This paradox has been brewing for some time, but the issue was brought to a head by a recent article by Gina Kolata in the New York Times titled, "Fearing Rare Side Effects, Millions Take Their Chances with Osteoporosis."3 This article, which garnered considerable attention in both the medical and lay community, was based, in part, on a paper by Jha and colleagues.4 published recently in the JBMR. Using an ecological analysis of media reports, oral bisphosphonate use, and fracture outcomes in the United States, the authors demonstrated a series of spikes in Internet search activity for alendronate between 2006 and 2010 immediately following media reports of safety concerns: specifically, osteonecrosis of the jaw (2006), atrial fibrillation (2008), and atypical femur fractures (2010). Coincident with media and public concern about these rare side effects, bisphosphonate use declined by greater than 50% from 2008 to 2012. Admittedly, some of this decline may reflect an appropriate response to advances in medical knowledge which helped clarify that bisphosphonates have limited efficacy in patients who are at low "short-term" risk of fracture.2 Other patients were stopped, also appropriately, because they had been on these drugs for many years, and evolving information helped us to recognize not only that osteonecrosis of the jaw and atypical femur fractures were associated with long duration of use, but also that the benefits of prolonged therapy were uncertain.2 However, there is increasing recognition that this decline also reflects the fact that many patients who clearly need osteoporosis therapy are not receiving it. This concern was confirmed by another recent study that used claims data from a U.S. commercial health plan (2004–2013) to evaluate the impact of U.S. Food and Drug Administration (FDA) announcements related to the potential risks of bisphosphonates on their use in patients with hip fracture.5 Although there are certainly controversies in the field of osteoporosis, there are also issues upon which there is complete or near-complete agreement: specifically, there is consensus that patients with hip fracture should receive pharmacological treatment to prevent additional fractures, because they are clearly at risk for recurrent hip or other osteoporotic fractures, and ini
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Black, D. M., & Rosen, C. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1513724 · Cited by 1,712
Bisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,124
Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur
Black, D. M., Kelly, M. P., Genant, H. K., Palermo, L., Eastell, R., Bucci-Rechtweg, C., Cauley, J., Leung, P. C., Boonen, S., Santora, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001086 · Cited by 512
Eisman, J. A., Bogoch, E. R., Dell, R., Harrington, J. T., McKinney, R. E., McLellan, A., Mitchell, P. J., Silverman, S., Singleton, R., Siris, E., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1698 · Cited by 383
Statins for the primary prevention of cardiovascular disease
Ebrahim, S., Taylor, F. C., & Brindle, P. (2014) · BMJ · doi:10.1136/bmj.g280 · Cited by 333
Jha, S., Wang, Z., Laucis, N., & Bhattacharyya, T. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2565 · Cited by 230
Kim, S. C., Kim, D. H., Mogun, H., Eddings, W., Polinski, J. M., Franklin, J. M., & Solomon, D. H. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2832 · Cited by 111
Selga, J., Núñez, J. H., Minguell, J., Lalanza, M. P. P., & Garrido, M. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3355-z · Cited by 65
Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy
Modi, A., Siris, E. S., Tang, J., & Sen, S. S. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1016605 · Cited by 48
Cited by
Compston, J. E., McClung, M. R., & Leslie, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32112-3 · Cited by 2,449
The clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
Osteoporosis treatment: recent developments and ongoing challenges
Khosla, S., & Hofbauer, L. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30188-2 · Cited by 1,019
Self-citationEastell, R., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Shoback, D. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00221 · Cited by 868
Tyagi, A. M., Yu, M., Darby, T. M., Vaccaro, C., Li, J.-Y., Owens, J. A., Hsu, E., Adams, J., Weitzmann, M. N., Jones, R. M., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.10.013 · Cited by 564
Metadata
- Authors
- Khosla, S., & Shane, E.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-06-22
- Volume
- 31
- Issue
- 8
- Pages
- 1485-1487
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2460799613
- Cited by
- 319
- References
- 10
- FWCI
- 49.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Crisis in the Treatment of Osteoporosis. https://app.cochat.ai/papers/10.1002/jbmr.2888
- The paper
- Khosla, S., & Shane, E. (2016). A Crisis in the Treatment of Osteoporosis. Journal of Bone and Mineral Research. https://doi.org/10.1002/jbmr.2888
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.